The Role of Faecal Bile Acids in the Management of Bile Acid Diarrhoea

Launched by THE ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST · Jul 25, 2016

Keywords

ClinConnect Summary

The prevalence of chronic diarrhoea is 5% of the population, a third of these cases have bile acid malabsorption (BAM).

SeHCAT (seleno-tauro-homocholic acid) testing is the gold standard for BAM, and involves the ingestion of seleno-tauro-homocholic acid, which is limited to a small number of UK centres. NICE reported that although SeHCAT might benefits patients, there was a need to explore alternative technologies.

With limited access to and cost of SeHCAT, many centres use an empirical trial of bile acid sequestrants, without a diagnosis. This may not be effective as many patients are n...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years age and over
• • Willing to provide informed consent
• • Post-cholecystectomy patients group (n=30; type 3 BAD)
• • Post-terminal ileal resection patients with Crohn's disease group (n=30; type 1 BAD)
• • D-IBS patients with normal SeHCAT retention group (n=30)
• • Idiopathic bile salt diarrhoea with abnormal SeHCAT retention group (type 2 BAD) (n=30)
• Exclusion Criteria:
• • Pregnancy/ breast feeding
• • Patient participating in another trial
• • Patients unable to give written consent
• • Known established bile salt diarrhoea
• • Recipients of antibiotics in under 4 weeks of initial trial participation